Creabilis Appoints George F. Horner III as its Chairman

LUXEMBOURG, September 15, 2010 - Creabilis SA, a clinical stage European biotechnology company
addressing significant unmet medical needs in dermatological diseases, today
announced the appointment of George F. Horner III as its Chairman. Mr Horner
brings to Creabilis an unrivalled track record in building successful biotech
businesses that have generated significant value for their shareholders.

Mr Horner has over 40 years industry experience gained with
both biotech and big pharma companies. He was most recently the CEO of
Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail
Corporation and Ovation Pharmaceuticals in late 2008. Prior to joining
Prestwick, Mr Horner was the CEO of Vicuron, a publicly listed
anti-infectives company that was sold to Pfizer for $1.9 billion in 2005. Mr
Horner also worked for Ligand Pharmaceuticals following a successful career
at Abbott Laboratories where his final position was as President of the
company's business in Canada. Mr Horner has also acted as an adviser to a
number of specialist life science investors in recent years.

Commenting on his new role, George F. Horner III said: "I am
excited to be joining Creabilis given its potential to deliver the genuine
innovation that is needed to transform the dermatology market. I have been
attracted to this opportunity by the Company's rich pipeline of clinical and
pre-clinical drug candidates focussed on dermatological indications, its deep
understanding of the science behind a number of serious skin disorders, as
well as its unique technology platform with broad utility. I am sure that
from this strong base we will be able to generate significant value for
Creabilis shareholders."

Graziano Seghezzi, Partner at Sofinnova, said: "We are
delighted to have someone with George's track record in building successful
high-value biotech businesses as Chairman of Creabilis. I am sure his
strategic and operational experience will be vital as we look to progress the
Company's exciting pipeline, build the management team and develop our LSE
(Low Systemic Exposure) technology, so that Creabilis can generate new
prescription medicines that will make a significant improvement to the
treatment of skin diseases."

About Creabilis SA

Creabilis is a clinical stage European biotechnology company
creating highly innovative new drugs to tackle unmet medical needs in serious
dermatological diseases. Bringing together world class drug development
capabilities and a rich scientific heritage, Creabilis is uniquely positioned
to transform the treatment of skin diseases.

Creabilis' lead product is CT327, a novel topically applied
TrkA kinase inhibitor developed using the Company's LSE (Low Systemic
Exposure) technology. LSE technology creates new chemical entities with ideal
characteristics for topical application (high local concentrations combined
with low systemic exposure). CT327 is currently in Phase II clinical trials
in psoriasis and atopic dermatitis. The Creabilis portfolio also includes
CT637, a new approach to the treatment of significant inflammatory conditions
such as rheumatoid arthritis as well as severe psoriasis. Earlier stage
projects include a number of highly promising candidates for dermatological
and wider indications.

Creabilis is backed by some of Europe's most highly respected
life sciences investors including Sofinnova Partners and Neomed.

For more information, please visit: www.creabilis-sa.com

    For further information please contact:
    Creabilis SA
    E-mail: info@creabilis-sa.com
    Creabilis SA
    15 Rue Edward Steichen
    L-2540 LUXEMBOURG

    Citigate Dewe Rogerson
    Chris Gardner or Nina Enegren
    Tel: +44(0)20-7282-1050
    E-mail: nina.enegren@citigatedr.co.uk

For further information please contact: Creabilis SA, E-mail: info at creabilis-sa.com, Creabilis SA, 15 Rue Edward Steichen, L-2540 LUXEMBOURG; Citigate Dewe Rogerson: Chris Gardner or Nina Enegren, Tel: +44(0)20-7282-1050, E-mail: nina.enegren at citigatedr.co.uk